New BCG vaccine could be just as good for bladder cancer
NCT ID NCT05037279
First seen Apr 12, 2026
Summary
This phase 3 trial is testing a new version of the BCG vaccine, called Verity-BCG, against the standard BCG treatment (OncoTICE) in 540 people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG before. The goal is to see if Verity-BCG is at least as effective at preventing cancer recurrence over 24 months. Participants will receive either Verity-BCG or OncoTICE through a catheter into the bladder, followed by maintenance doses for up to 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 01
RECRUITINGToronto, Ontario, Canada
Contact
-
Site 02
NOT_YET_RECRUITINGToronto, Ontario, Canada
Contact
-
Site 04
RECRUITINGKingston, Ontario, Canada
Contact
-
Site 05
RECRUITINGVancouver, British Columbia, Canada
Contact
-
Site 08
RECRUITINGToronto, Ontario, Canada
-
Site 10
NOT_YET_RECRUITINGMontreal, Quebec, Canada
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bacillus Calmette-Guerin (BCG) vaccine
What this could lead to
If it works, this could offer a new, equally effective BCG option for bladder cancer patients, potentially improving drug supply and access.
What could go wrong
This is a non-inferiority trial, meaning it only aims to show Verity-BCG is not worse than the current standard. Even if successful, it may not be better. The trial is still recruiting, so results are years away.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.